MOTS-c

MOTS-c (Mitochondrial peptide) is a mitochondrial ORF (16 amino acids). The HEIVE catalog describes it as: A mitochondria-encoded peptide that mimics parts of the exercise response in mice. It is also known as Mitochondrial ORF of the 12S rRNA-c.

HEIVE groups MOTS-c under mitochondrial function, fatigue, oxidative stress, energy crashes and workout energy. These catalog categories are not approved indications or evidence that treatment works. See the product-specific regulatory answer below.

No matching FDA product was identified for MOTS-c under the searched names in the October 6, 2026 Drugs@FDA snapshot. This name search does not establish worldwide approval status or exclude differently named products. FDA describes safety concerns or insufficient safety information for the corresponding substance on its compounding-risk page; that listing is not a drug approval.

• FDA product data (October 6, 2026)
• FDA compounding safety information

The HEIVE editorial risk summary for MOTS-c lists: Injection-site reaction; some report a warm flush. Longer-term concerns: Discovered in 2015. There is no long-term data because there has not been time. This is not a complete or clinically reviewed safety assessment; risks depend on the product, route and population.

MOTS-c has no single onset time established by this catalog. The editorial timeline starts with “Days 1–7”. These are illustrative model or editorial milestones, not clinically validated outcome predictions.

HEIVE's illustrative catalog entry for MOTS-c: 5–10 mg, three times weekly. This is not a verified study range or a prescription. A dose cannot be transferred between products, routes or indications; use the specific approved label and the prescribing clinician's instructions where applicable.

The catalog classifies MOTS-c as mainly preclinical. Its paper-count snapshot is not a live PubMed search, a count of controlled human trials or proof of safety. This FAQ has not independently validated the catalog's clinical literature claims.

The source catalog lists only injectable forms for MOTS-c; it does not establish that every studied or marketed form is injectable.

Preparation of MOTS-c depends on the exact labeled product. Follow its instructions for formulation, diluent, route and storage. A generic powder recipe must not be applied to a prefilled, ready-to-use or differently formulated product. The catalog's mixing example does not establish sterility or stability.

Storage for MOTS-c depends on the specific formulation (injectable in the source catalog). Follow the product's labeled temperature, light protection and expiry or discard instructions. A general refrigerator or 28-day rule does not establish stability or sterility for every preparation.

The HEIVE editorial summary for MOTS-c: Typically cycled 4–6 weeks with equal time off. This summary is not a clinically validated prediction of tolerance or withdrawal for an individual.

MOTS-c and SS-31 share the catalog categories mitochondrial function, oxidative stress and fatigue. MOTS-c: A mitochondria-encoded peptide that mimics parts of the exercise response in mice. SS-31: Binds cardiolipin in the inner mitochondrial membrane; in late-stage trials for primary mitochondrial myopathy. This is a catalog comparison, not a head-to-head clinical result or a recommendation to substitute treatments.

• View SS-31

The HEIVE editorial summary highlights: Mice on it ran further without training. The mechanism is still argued over. The cited study, population and formulation must be checked before treating this summary as a clinical finding; this FAQ does not supply a verified research citation for it.